I havent mentioned the attempt by Bristol-Meyers Squibb to buy out Imclone until now, but theres a nice . The reasons for the move are unsurprising BMS would like all the revenue from Erbitux, instead of just a share of it, and sees some value coming up in Imclones pipeline (such as their development drug candidate IMC-11F8, vide infra). Theyve waiting quite a while, and apparently feel that the time is right the...